Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8825578 | 1.00 | ACHE (0.64) | ACHEKDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL6953531 | 0.94 | ACHE (0.55) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL5475624 | 0.92 | ACHE (0.53) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL31596884 | 0.91 | GPR119 (0.53) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL23884184 | 0.90 | ACHE (0.51) | ACHEKDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL12635860 | 0.89 | KDM4E (0.56) | ACHEKDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL29558262 | 0.87 | KDM4E (0.54) | ACHEKDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL27038680 | 0.87 | KDM4E (0.54) | ACHEKDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL7516299 | 0.87 | KDM4E (0.49) | ACHEKDM4EPKMGPR119BRD4 | |
| SCHEMBL30802084 | 0.87 | KDM4E (0.49) | ACHEKDM4EPKMGPR119BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | ACHE 2876/4885KDM4E 4275/4885PKM 2269/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | ACHE 2876/4885KDM4E 4275/4885PKM 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.